Your Health, We Care
Kidney International has released Phase 2 clinical study 1 of sparsentan, in which blood pressure was well controlled in all patients.
Sparsentan is a type of factor B inhibitor that has complement inhibitory effects and has relatively little impact on the immune and endocrine systems. It has a relatively low risk of serious adverse events and may be used to treat IgA nephropathy.
